Alice B. Gottlieb

48.8k total citations · 15 hit papers
602 papers, 31.4k citations indexed

About

Alice B. Gottlieb is a scholar working on Immunology, Dermatology and Rheumatology. According to data from OpenAlex, Alice B. Gottlieb has authored 602 papers receiving a total of 31.4k indexed citations (citations by other indexed papers that have themselves been cited), including 475 papers in Immunology, 218 papers in Dermatology and 204 papers in Rheumatology. Recurrent topics in Alice B. Gottlieb's work include Psoriasis: Treatment and Pathogenesis (443 papers), Dermatology and Skin Diseases (162 papers) and Spondyloarthritis Studies and Treatments (157 papers). Alice B. Gottlieb is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (443 papers), Dermatology and Skin Diseases (162 papers) and Spondyloarthritis Studies and Treatments (157 papers). Alice B. Gottlieb collaborates with scholars based in United States, Canada and United Kingdom. Alice B. Gottlieb's co-authors include Alan Menter, Craig L. Leonardi, Mark Lebwohl, James G. Krueger, Kenneth B. Gordon, Steven R. Feldman, Philip J. Mease, Kim Papp, Neil J. Korman and John Koo and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Alice B. Gottlieb

579 papers receiving 30.2k citations

Hit Papers

Guidelines of care for the management of ... 1989 2026 2001 2013 2008 2003 2005 1989 2016 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Guidelines of care for the management of psoriasis and psoriatic arthritis
    2008 964 citations Alice B. Gottlieb, Mark Lebwohl et al. profile →
  2. Etanercept as Monotherapy in Patients with Psoriasis
    2003 935 citations Alice B. Gottlieb et al. profile →
  3. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial
    2005 852 citations Alice B. Gottlieb, Kim Papp et al. profile →
  4. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes.
    1989 740 citations James G. Krueger, Alice B. Gottlieb et al. profile →
  5. Psoriasis
    2016 687 citations Mark Lebwohl, Alice B. Gottlieb et al. profile →
  6. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
    2015 650 citations Iain B. McInnes, Philip J. Mease et al. profile →
  7. Guidelines of care for the management of psoriasis and psoriatic arthritis
    2008 612 citations Alice B. Gottlieb, Mark Lebwohl et al. profile →
  8. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
    2013 606 citations Iain B. McInnes, Alice B. Gottlieb et al. profile →
  9. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
    2014 508 citations Christopher T. Ritchlin, Proton Rahman et al. Annals of the Rheumatic Diseases profile →
  10. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies
    2018 444 citations Lars Erik Kristensen, Alice B. Gottlieb et al. profile →
  11. A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis
    2016 376 citations Kim Papp, Kristian Reich et al. British Journal of Dermatology profile →
  12. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
    2020 242 citations Philip J. Mease, Proton Rahman et al. profile →
  13. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations
    2019 224 citations Afsáneh Alavi, Alice B. Gottlieb et al. profile →
  14. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations
    2019 222 citations Afsáneh Alavi, Alice B. Gottlieb et al. profile →
  15. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
    2024 71 citations Alexa B. Kimball, Gregor B. E. Jemec et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alice B. Gottlieb United States 90 23.1k 12.3k 8.9k 5.4k 3.5k 602 31.4k
Kim Papp Canada 85 24.4k 1.1× 16.3k 1.3× 7.2k 0.8× 4.1k 0.8× 4.3k 1.2× 542 32.6k
Alan Menter United States 80 19.1k 0.8× 12.2k 1.0× 4.7k 0.5× 2.6k 0.5× 3.5k 1.0× 387 25.4k
Kristian Reich Germany 80 20.2k 0.9× 14.0k 1.1× 5.0k 0.6× 2.8k 0.5× 3.7k 1.1× 497 26.2k
Mark Lebwohl United States 94 23.0k 1.0× 18.1k 1.5× 5.7k 0.6× 2.8k 0.5× 5.1k 1.5× 847 36.1k
Joel M. Gelfand United States 77 14.3k 0.6× 9.1k 0.7× 5.1k 0.6× 1.7k 0.3× 2.4k 0.7× 283 21.7k
Richard G. Langley Canada 67 14.7k 0.6× 9.6k 0.8× 3.4k 0.4× 2.3k 0.4× 2.7k 0.8× 264 19.1k
Juliet N. Barker United States 85 17.3k 0.7× 9.0k 0.7× 2.8k 0.3× 8.4k 1.6× 2.6k 0.7× 559 31.3k
L. Puig Spain 57 11.2k 0.5× 7.7k 0.6× 3.8k 0.4× 2.2k 0.4× 2.2k 0.6× 626 18.2k
Giampiero Girolomoni Italy 81 12.5k 0.5× 9.9k 0.8× 3.7k 0.4× 1.1k 0.2× 2.0k 0.6× 558 23.7k
Craig L. Leonardi United States 45 11.4k 0.5× 6.4k 0.5× 2.6k 0.3× 1.7k 0.3× 2.0k 0.6× 133 14.1k

Countries citing papers authored by Alice B. Gottlieb

Since Specialization
Citations

This map shows the geographic impact of Alice B. Gottlieb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alice B. Gottlieb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alice B. Gottlieb more than expected).

Fields of papers citing papers by Alice B. Gottlieb

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alice B. Gottlieb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alice B. Gottlieb. The network helps show where Alice B. Gottlieb may publish in the future.

Co-authorship network of co-authors of Alice B. Gottlieb

This figure shows the co-authorship network connecting the top 25 collaborators of Alice B. Gottlieb. A scholar is included among the top collaborators of Alice B. Gottlieb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alice B. Gottlieb. Alice B. Gottlieb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lebwohl, Mark, Melinda Gooderham, Richard B. Warren, et al.. (2025). Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasis. Clinical and Experimental Dermatology. 50(10). 2030–2036.
2.
Augustin, Matthias, Alice B. Gottlieb, Mark Lebwohl, et al.. (2024). Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis. Dermatology and Therapy. 14(10). 2841–2857. 6 indexed citations
3.
Armstrong, April W., Alice B. Gottlieb, Jeffrey M Weinberg, et al.. (2024). Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel. Journal of Drugs in Dermatology. 23(8). 592–599. 2 indexed citations
4.
Gottlieb, Alice B., et al.. (2024). GRAPPA Point-Counterpoint: Should Biologics Be Used for Mild Psoriasis?. The Journal of Rheumatology. 51(Suppl 2). 39–42.
5.
Kimball, Alexa B., Afsáneh Alavi, Gregor B. E. Jemec, et al.. (2023). Secukinumab in Moderate to Severe Hidradenitis Suppurativa: Primary Endpoint Analysis From the SUNSHINE and SUNRISE Phase 3 Trials. SKIN The Journal of Cutaneous Medicine. 7(2). s129–s129. 5 indexed citations
6.
Navrazhina, Kristina, Yael Renert‐Yuval, Saakshi Khattri, et al.. (2023). 148 Tape strips detect molecular alterations and cutaneous biomarkers in hidradenitis suppurativa skin. Journal of Investigative Dermatology. 143(11). S357–S357. 1 indexed citations
7.
Gottlieb, Alice B., Russel Burge, William N. Malatestinic, et al.. (2023). Achievement of the National Psoriasis Foundation Treatment Treat-to-Target Goals in the US Ixekizumab Customer Support Program. SKIN The Journal of Cutaneous Medicine. 7(3). s201–s201. 2 indexed citations
8.
9.
Blauvelt, Andrew, Diamant Thaçi, Kim Papp, et al.. (2023). Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials. British Journal of Dermatology. 189(1). 132–134. 8 indexed citations
10.
Puig, L., Siew Eng Choon, Alice B. Gottlieb, et al.. (2023). Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease management. Journal of the European Academy of Dermatology and Venereology. 37(4). 737–752. 39 indexed citations
11.
Gottlieb, Alice B., et al.. (2023). Successful Treatment of Morphea with Topical Ruxolitinib. SKIN The Journal of Cutaneous Medicine. 7(2). 747–749.
12.
Mease, Philip J., Alice B. Gottlieb, Alexis Ogdie, et al.. (2023). Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment. Clinical Rheumatology. 43(1). 241–249. 1 indexed citations
13.
Blauvelt, Andrew, C. Paul, P.C.M. van de Kerkhof, et al.. (2020). Long‐term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo‐controlled studies. British Journal of Dermatology. 184(4). 640–651. 15 indexed citations
14.
Ritchlin, Christopher T., Mona Ståhle, Yves Poulin, et al.. (2019). Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics. BMC Rheumatology. 3(1). 52–52. 25 indexed citations
15.
Nash, Peter, Philip Mease, Iain B. McInnes, et al.. (2016). Secukinumab Safety and Tolerability in Patients with Active Psoriatic Arthritis and Psoriasis: Results From a Pooled Safety Analysis. Internal Medicine Journal. 46. 39–39. 2 indexed citations
16.
Gottlieb, Alice B., Philip Mease, Iain B. McInnes, et al.. (2014). Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from a Phase 3 Randomized Controlled Trial. Queensland's institutional digital repository (The University of Queensland). 66. 12 indexed citations
17.
Phillips, Tania J., Alice B. Gottlieb, William D. James, et al.. (2002). Efficacy of 0.1% Tazarotene Cream for the Treatment of Photodamage. Archives of Dermatology. 138(11). 1 indexed citations
18.
Dowell, James A., Alice B. Gottlieb, Anton Leighton, et al.. (2002). The pharmacokinetics and renal excretion of dalbavancin in healthy subjects. 42. 18. 9 indexed citations
19.
Gilleaudeau, Patricia, et al.. (1994). PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy.. The Journal of Experimental Medicine. 180(1). 283–296. 139 indexed citations
20.
Gottlieb, Alice B., et al.. (1988). Detection of transforming growth factor alpha in normal, malignant, and hyperproliferative human keratinocytes.. The Journal of Experimental Medicine. 167(2). 670–675. 206 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kim Papp Breakdown of academic impact, for papers by Alan Menter Breakdown of academic impact, for papers by Kristian Reich Breakdown of academic impact, for papers by Mark Lebwohl Breakdown of academic impact, for papers by Joel M. Gelfand Breakdown of academic impact, for papers by Richard G. Langley Breakdown of academic impact, for papers by Juliet N. Barker Breakdown of academic impact, for papers by L. Puig Breakdown of academic impact, for papers by Giampiero Girolomoni Breakdown of academic impact, for papers by Craig L. Leonardi
Rankless by CCL
2026